Procaps Group, S.A. (PROC) News
Filter PROC News Items
PROC News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
PROC News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest PROC News From Around the Web
Below are the latest news stories about PROCAPS GROUP SA that investors may wish to consider to help them evaluate PROC as an investment opportunity.
Procaps Group Receives Additional Delinquency LetterMIAMI and BARRANQUILLA, Columbia, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical services company, today announced that, as anticipated, on December 31, 2024, the Company received notice from The Nasdaq Stock Market LLC (“Nasdaq”) of an additional filing delinquency relating to the Company’s interim financial statements for the period ended June 30, 2024. The interim financial statements |
Procaps Group Announces Key Shareholder and Board Decisions, Committee Restructuring, and Leadership UpdatesMIAMI and BARRANQUILLA, Colombia, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical services company, today announced significant outcomes from its recent Shareholders Meeting and subsequent Board of Directors meeting. These include changes to the Board composition, restructuring of Board committees, and updates to its executive leadership team. The Shareholders Meeting marked an important m |
A Look At The Intrinsic Value Of Procaps Group S.A. (NASDAQ:PROC)Key Insights The projected fair value for Procaps Group is US$3.24 based on 2 Stage Free Cash Flow to Equity With... |
Procaps Group Announces Financing, Shareholders Agreement and Board UpdatesMIAMI and BARRANQUILLA, Colombia , Dec. 03, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical services company, today announced the successful execution of key strategic transactions and governance updates aimed at strengthening its financial position and supporting long-term growth objectives. On November 29, 2024, the Company entered into a Secured Convertible Note Subscription Agreement with Hoche |
Procaps Receives Nasdaq Listing Determination; To Request Hearing and Further Stay Pending HearingMIAMI and BARRANQUILLA, Colombia, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), announced today that, on November 13, 2024, the Company received formal notice from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that, based upon the Company’s failure to timely file the Form 20-F for the fiscal year ended December 31, 2023 (the “Form 20-F”) with the U.S. Securities and Exchange Commission (the “SEC” |
Procaps Issues Shareholder Letter UpdateMIAMI and BARRANQUILLA, Colombia, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical services, today issued the below letter to shareholders from José Antonio Vieira, CEO of Procaps, providing critical updates on the Company’s ongoing independent investigation, financial restatement, governance enhancements, and commitment to long-term stability. “Dear Shareholders, As we navigate recent chal |
With 60% ownership, Procaps Group S.A. (NASDAQ:PROC) insiders have a lot riding on the company's futureKey Insights Insiders appear to have a vested interest in Procaps Group's growth, as seen by their sizeable ownership... |
Procaps Issues Shareholder LetterMIAMI and BARRANQUILLA, Colombia, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical conglomerate, today issued the below letter to shareholders from José Antonio Vieira, CEO of Procaps, addressing the current state of the business and outlining key strategic priorities for the Company. “Dear Shareholders, When I began my tenure as CEO of Procaps in January 2024, I made a commitment to formu |
Procaps Group Announces New ChairmanMIAMI & BARRANQUILLA, Columbia, June 28, 2024--Procaps Group, S.A. (NASDAQ: PROC) ("Procaps" or the "Company"), a leading integrated LatAm healthcare and pharmaceutical conglomerate, announced that Mr. Ruben Minski has resigned from his role as Executive Chairman of the Board, effective June 30th. Mr. Minski will continue to serve as a member of the Board of Directors. |
Procaps Group Receives Nasdaq Notice Related to Late Filing of its Form 20-FMIAMI & BARRANQUILLA, Colombia, May 20, 2024--Procaps Group Receives Nasdaq Notice Related to Late Filing of its Form 20-F |